Untilabout 50y ears ago,the alteringofanormaldruge ffectbyag enetic deficiencyw aso nly rarely observed.Here, my discovery ofthe genetic variant ofb utyrylcholinesteraseaffectingsuccinylcholineaction isdescribed insomedetail. Such discoveriesl ed to the combination ofthe two olders ciences,g eneticsandpharmacology,therebyformingpharmacogenetics. Aftert he discovery ofsimilarexamplesin the years thatfollowed, pharmacogeneticsexpanded on the basisoftwo discoveries. First,the common occurrence ofinterethnic differences indrugresponseand, secondly,the factthatmost pharmacologicaldifferencesweremultigenic.Newmethodologiesbroughtatransition to pharmacogenomics; thisincluded detection ofc linically important genetic variants andh asu ncovered potentially newdrugtargets. The arrivalo fpersonalised medicine-whereapatient'sgenesdeterminethe choice ofd rugto be administered -canbe hoped to gradually improved rugsafety ande fficacy. Efforts to reach thisl evelo fperfection are, however,d ogged byu ncertainties.
Introduction
Pharmacogenomicsandpharmacogeneticsaretwoclosely related andoverlappingsciences. Itw asonly relatively recently thatp harmacogenomicsarosef romp harmacogenetics,mainly reflectingtechnicalimprovements which arec hangingsome outlooks,a sw ill be described.The change paralleled the broadeningofc lassicalgeneticsinto genomics.
Pharmacogeneticsarosefromthe meldingofthe older sciences,pharmacologyandgenetics. The recognition that therearehealingsubstancesofthe kindthatw enowcall 'drugs' iscertainly thousandsofyears old;Egyptianmedical papyricontainnumerous prescriptions. 1 Moreover,observations ofhumanandanimalinheritancesw erereported inearly Greek papers. 2 Bothpharmacologyandgeneticsbecamerecognised sciencesonly inthe 18thcentury,however-pharmacologythrough the workofClaude BernardandOswald Schmiedeberg, 1 geneticsthrough Gregor MendelandFrancis Galton. 2 Pharmacologyandgeneticsremained separatesciences until1931,whenSirArchibaldGarrodanticipated the existence ofpharmacogeneticsinhisbook InbornFactors inDiseases . 3 In1949,J .B.S.Haldanepredicted the occurrence ofunusual reactions to drugsonthe basisofbiochemicalindividuality. 4 Infact,b y1 949,afewisolated caseso fg enetic differences indrugresponseh ad beens een. In1 932,the ability to tastethe chemicalp henylthiocarbamide (PTC)andthe lack ofi tw ereshownt obe inborncharacteristics. 5 In1 937, Wa ldenströmdescribed drug-induced porphyria. 6 The genetic lack ofa tropinee sterasei nr abbits wasdemonstrated in1 943. 7 The SecondW orldW arr evealed ah aemolytic diseasewhich wascaused byt he antimalarialdrugprimaquineonly in Americans oldiers ofA fricandecent; its genetic basisw asfully established aftert he war. 8, 9 Pharmacogeneticsbecamea nestablished science int he 1950s. First,thereweref urtherdiscoveries; for example, the genetic deficiencyo fN -acetyltransferase, the enzymewhich destroyed the thenr evolutionary anti-tuberculosisdrug isoniazid. 10, 11 Atabout the sametime, Id iscovered ag enetic variation ofb utyrylcholinee sterase(thencalled 'plasmac holinesterase'or'pseudocholinesterase'),avariation which caused fatalr esponsest os uccinylcholine, ad rugused duringa naesthesia. 10 Secondly,i n1 957,M otulskys ummarised all then availabledatainapaperentitled 'Drugreactions,enzymes,and biochemicalgenetics',apapers ponsored byt he Councilo n Drugso fthe AmericanMedicalAssociation. 12 In1 959,V ogel published the word'pharmacogenetics'. 13 The discovery to be described wasbased on eventsinthree cities:Berlin,PhiladelphiaandT oronto.The experience began my life-longi nvolvement withpharmacogeneticsandled me to participatei nt he furtherdevelopment ofthisarea ofstudy.
Berlin
The cholinesterasestory had anindirectstartingpoint afterthe SecondW orldW arinBerlin,c loseto my home.Nutrition wass till generally poor,which oftenaffected the stateof people's health;l ocalr esearch 14 showed thatl ow levels of nutrition lowered the concentration ofsomeproteins.When af ewp eopled ied frominjection ofthe old-andg enerally considered safe -localanaesthetic procaine, ad ietary change ofaproteinl evelw ass uspected.Procainewasknown to be safe because, afterits injection,itwasusuallyquickly destroyed byanenzymec alled procainee sterase. 15 Myboss,the pharmacologist DrHerken,suspected thatp oor nutrition int hese patientshad lowered theirp rocainee steraselevels,thereby enablingthe drugto kill them.
He askedme, ayoungi nvestigatoratthattime, to studythe effectofnutrition on procaineesteraselevels. For thispurpose, Iwast ou seultravioletp hotometry; 16 usingultravioletl ight, weh oped to be ableto measurethe levelo fprocainei nt he plasma.The production ofultravioletlightw asdifficult atthat timeinBerlin; the equipment required repeated attention bya physicist,a ndwewereonly ableto measurethe lightintensity becausethe occupyingUSarmyhad donated aphotometert o BerlinUniversity.Myexperiments showed thatt he method wasableto measureprocaineconcentrations inhumanplasma, andtherebyp rocained estruction.
Sometimea fterIh ad started thisw orki nBerlin,my experiments wereterminated.Sponsored bythe US Unitarian Church, ag roup ofA mericanScientistsv isited BerlinUniversity,a ndoneofthe scientists( DrCarl F.Schmidt) invited meto comef or ayearo fstudyt ohisDepartment ofP harmacologyatt he University ofP ennsylvania inPhiladelphia. Thisw asawonderful turno fe vents,a ndshortly afterwards Itravelled to Philadelphia.
Philadelphia
Int he Department ofP harmacologyinPhiladelphia, Iwas kept busy participatingi nl arge cardiovascularexperiments, andIalso did someteaching.Byt alkingwithvarious investigators,Ilearned thatt he department owned aB eckman spectrophotometer,alittleb ox on ab ench top thatcouldd o the ultravioletw orkthatinBerlinhad required awholeroom andthe help ofaphysicist. Iwasallowed to usethisinstrument whenitwasfree,which wasmostly atnight. Iwasdelighted to notethat,withthiss pectrophotometer,Icouldmeasurethe destruction ofprocaine, asIh ad donei nBerlin. Playing around, Itried otherchemicals andtherebyfoundthatt he procaine-destroyinge nzymea lso destroyed benzoylcholine, a substance known to be asubstratef or plasmac holinesterase. 17 Thus,Ihad discovered anewm ethodofmeasuringthis cholinesterasea ctivity,a ndmy datai ndicated thatp rocaine esterasewasactually ac holinesterase.WhenItried to publish thisenzymei dentity inab iochemicaljournal,the paperw as rejected asu seless,on the mistakenassertion thathuman plasmawasknown to haveonly onee sterase(therea renow known to be many!). Thepaperw asp ublished bya pharmacologicaljournal. 18 Oned ay,aco-student introduced meto DrBritton Chance,the famoushead ofthe Johnson Foundation in Philadelphia.DrChance foundmy studieso np lasmac holinesterasei nterestinga ndoffered help whenevern eeded. He invited meto visithisfoundation andto attendlectures. Itherebyr eceived instruction inenzymek inetics,afield unfamiliart om any pharmacologists. Thisknowledge laterl ed meto animportant research decision.
Myo riginalinvitation to studyp harmacologyinPhiladelphia wasfor ayear,b ut afterawhileD rSchmidtinvited me to becomeapermanent membero fh isdepartment. Iwas happyt oaccept,h owever,thisr equired ac hange to my student visato animmigration visa.The simplest wayt ogett his change wast ol eavethe USA andto formally immigratef rom Canada.Ithereforeprepared for this.
Toronto
Aspecialexperience made mea imfor Toronto inCanada: DrJ.K.W.Ferguson,c hief ofthe Department ofP harma-cologyinToronto,attended aUSmeetingwhereIgaveatalk. Afterwards,h ei nvited meto visithiminToronto whenever possible;t hus,Ihoped to immigrateto the USA from Toronto.WhenImetDrFerguson inToronto,weh ad some interestingc onversations andh ei nvited meto takeup a permanent position inhisdepartment. Ia ccepted hisinvitation,partly becauseofa nu nusualbut pleasant experience: whileIwasinToronto,the futureQ ueenElizabetha ndh er husbandvisited the city; theyr ode inano pencar,without safety guards,through the streets andthe University campus, amidst friendly cheeringb yt he crowds. Thisw asins trong contrast to the ecstatic reception ofG eneralMcArthur on hisr eturnt ot he USA fromt he KoreanWa r; thiselation reminded meofaHitlerr eception which Ih ad experienced asayouthi nGermany.Itw aso bvious to methatCanadians had aquieterm entality thanm any Americans,a ndIconsequently felt thatl ife inCanada wouldb eb ettert hanint he USA -andb ettert hanithad beeninGermany.WhenI wroteto Philadelphia, askingf or DrSchmidt'so pinion,h e wished meg oodluck inToronto.
Inoticed thats tudieso fc holinesterasewereb eingpursued inToronto.Whilethe discovery ofc holinesterasei nt he early 1920s had earned DrOtto Loewi, inAustria, the Nobel Prize, the DutchmanBruno Mendelandh iscolleague H.Rudney,workinginToronto,discovered in1943thatthere werea ctually twodifferent cholinesterases:oneoccurringi n Kalow Review HISTORICAL PERSPECTIVE red bloodc ells andi nt he centraln ervous system, 17 andthe othero nly int he plasma.Theycalled the onei nr ed blood cells 'truec holinesterase'andthe onei nt he plasma'pseudocholinesterase'. Truec holinesterasewaso bviously important, actinga tn ervee ndingst odestroy the transmitters ubstance acetylcholine.The function ofpseudocholinesterasewasa puzzle, andwass till underbiochemicalinvestigation when Ia rrived inToronto.Ih earda bout thiso ngoingresearch and learned thatt he investigatorsw erestill usingthe traditional gasometric methodto determinec holinesterasea ctivity.This methodwasl abour intensivea ndc omplicated, requiring precisemeasurements ofC O 2 gas,which wasl iberated in minutequantitiesbycholinesterasea ction. Itoldthe investigatorst hatIh ad amuch betterm ethodf or measuringthe enzymea ctivity andtheyaskedmeto demonstrateacomparison betweent he twom ethods.
Ireceived bloodd onations fromanumbero fstudents, measured theircholinesterasea ctivity usingb othmethods andf oundthatt he results correlated very well. 19 The biochemistsw erestill not satisfied;asall ofmy tested students had esterasea ctivity int he normalr ange,theyw anted to knoww hetherm yt est wouldproperlyindicatec aseso flow activity.
DrFerguson knewhow wec ouldfi ndsuch cases. Certain patientsw ithmentalhealthproblems wereroutinely given electroshock treatments,since therewereno effectived rugs att hatt ime.Theshock wasp roducedb yapplication ofa n electric charge to the skull,a ndtherebyt ot he brain. Aside effecto fthist reatment wass ometimesano ccurrence of severemusclec ontractions,severee nough to break ab onei n the patient.Toavoid thiss ide effect,patientsr eceived an injection ofsuccinylcholineprior to the shock application; succinylcholine, ad epolarisingb lockero fa cetylcholine action,prevented the musclec ontractionsw ithout affecting the mentalbenefito fthe shock.The treatment usually required multipleshock treatments overt he courseofweeks or months.
Alocalp hysicianknewp atients inw hom succinylcholine did not just actfor af ewm inutes,a sw asu sually the case, but whor emained paralysed byitfor about anhour. Thisp rolonged action ofsuccinylcholinewasknown to be caused by animpairment ofplasmac holinesterase, which normally broughtabout the rapid breakdowno fthe drug. 20 Te sts ina government laboratory had confirmed lowcholinesterase activity ins uch patents.Ithereforereceived bloodsamples froms omeofthesepatientss ot hatIc ouldtest theircholinesterasea ctivity usingmy ultravioletm ethod.
WhenImeasured the enzymeactivity via the destruction of benzoylcholinei nt hesepatients,Inoticed thatt he reaction wass trange.Usually,the disappearance rateofb enzoylcholine followed astraightl ineuntilt he reaction wasfinished, usually withinaf ewm inutes. Int he plasmaofthe 'special' patients, however,the disappearance ratewasn ot straightbut curved; the initialr eaction ratewasn ormalbut thengradually slowed down,so thatitt ookalongtimef or the reaction to finish. Ih ad learned enough enzymek inetics 21, 22 byt hent or ealise thatt he enzyme-substratea ffinity wasl ow;t hatis,therewas poor bindingb etweenenzymea ndsubstrate.Ishowed that therewereno enzymei nhibitorsint he tested plasma.Thus, the reduced affinity couldonly haveb eencaused byastructuralchange int he enzymeprotein. Such ac hange wasl ikely to haveagenetic cause.
Tot est thishypothesis,Iaskedf or aninvestigation ofthe relativeso fthe patientsandthereaftero btained plasmaf rom patients' parents. The destruction ofb enzoylcholinei nt hese plasmasamplesw asn eithern ormaln or asabnormalast hatin thatofthe patients. Furtherinvestigation tookalongtime, but Ifi nally foundasubstance called dibucaine, which strongly inhibited the normalenzymeb ut hardly touched the patient's enzyme; 23 the esteraseactivity ofthe parent sampleswaspartly inhibited.Itw ascleart hatt he patientsw erehomozygous,and the parents heterozygous,carriers ofthe enzymevariant,while the normals ubjects had the wild-typee nzyme.Itw ast he clearest possibled emonstration ofthe control ofaphenotypic characterbyastructural,a ndreadily measurable, variant of ag ene.Ve ry fewequivalent humancasesw erek nown at thatt ime.
Iwasexcited bym yfinding, which indicated thatagenetic variant altered adrugresponse.Iwondered whethert hiswasa uniqueobservation or whethert herewereothers uch cases. Isearched the literaturea ndf oundsomeofthe above-quoted casereports. Istill considered the factt hatag enemayaffect ad rugresponseto be anexcitingb ut generally unknown truth.Idecided to writeabookabout thistopic.Ittookafew years andc onsiderablee ffort; my book, entitled Pharmacogenetics:H eredity andthe Responseto Drugs ,c ameout in1 962. 24 Furthers tudieso nt hist opic becamethe purposeofmy scientific life.
The development of pharmacogenetics
The followingyears broughtt he recognition ofmany new pharmacogenetic examples. 25 For instance,theresoon came the discovery ofvariablephenytoinhydroxylation,a cetophenetidined ealkylation andparaoxonasea ctivity.Of particular importance int he late1970s wast he discovery ofthe cyto-chromeC YP2D6v ariation,a nenzymemetabolisingd ebrisoquinea ndsparteinenowknown to also metabolisea nd about 65otherdrugs. 26 Of wide interest also wast he finding ofvariablee thanol metabolism; 27 slowm etabolism leads peopleto reduce alcohol consumption andtherebyt ol ess alcohol addiction.Many moree xamplescouldb ec ited,not only concerningd rug-metabolisinge nzymes,b ut also variability ofd rugtransporters andofreceptors. Pharmacogenetics waso nits way. Thenext,f undamental,d iscovery inp harmacogeneticsw ast hato fpopulation differences.
Humanpharmacogenomics:T he development ofascience
Review HISTORICAL PERSPECTIVE
Population differences
The frequent occurrence ofpopulation differencesindrug responsesr epresents animportant aspecto fpharmacogenetics. Itw asastrange coincidence thatdrewm yearly attention to thisfact. Out ofc uriosity,students andc olleaguesinm yl aboratorys tudied the metabolic glucuronidation ofa mobarbital, ano lda ndsafe barbiturated rugwidely used att hatt ime. We happened to findthats omemembers ofafamily could not metabolisethisdrug;w eobviously had discovered anew genetic deficiency. 28 We thereforeseto ut to discoverw hether thiswasarareor afrequently occurringdeficiency. 29 We asked our class of140students to volunteertotakethe drugandthen supply aurinesample.The laboratoryt ests showed average metabolism inm osts tudents,b ut sevens ampleshad much moreofthe metabolitethandid the others.Isuspected a laboratory error andh oped to retest thesestudents. Ic ould only identifys tudents byt heirallocated numbers andd id not knowt heirn ames. Ig aveacolleaguethe numbers ofthoseto be retested;afewminuteslater,hecameback to meexcitedly, tellingmethatt he numbers Ih ad givenhimall belonged to subjects withC hinesenames.
Retestingofthe suspiciousurinesamplesshowed thatthere had not beenalaboratory error. 30 Furthermore, therewereno otherChinesestudents int he class besidest hoseretested. WhenI, ofE uropeano rigin,tested my ownm etabolism of amobarbitalalongwiththato fasouth-east Asiancolleague, our personalm etabolic capacitiescorrelated withthoseseen int he students. We thereforeh ad stronge vidence for an ethnic difference indrugmetabolisingc apacity.
Bycoincidence,the genetic control ofthe metabolism of debrisoquineh ad just beendiscovered, 31 but becauseofour interest inp harmacogenetics,wea lso tested thisinm yl aboratory. Bychance,wenoticed thats tudentso fC hineseorigin metabolised debrisoquinesignificantly moreslowlyt han thoseofE uropeano rigin 32 -a difference laterexplained in Swedenbyag enetic enzymea lteration. 33 Its eemed to us that wehad foundasecondethnic difference indrugmetabolism!I searched the literature, foundmoree xamplesandpublished the availabled ata. 34 Todate, many ethnic differencesindrugresponseh ave beenr ecognised.Arecent surveyenumerated 42drug-metabolisingenzymesthatshow differencesbetweenpopulations. 35 Inaddition,therea repopulation differencesbetweendrug receptorsandtransporters.The differencesareoftwokinds: therea reoftendifferencesint he frequencyo fagivenv ariant betweent wo populations,b ut,i naddition,the kindso fvariants maydiffer. Infact,the frequencieso fg ivenv ariants are moreoftendifferent thanidenticalingeographically separated populations.
Itisinterestingto considert he roots ofsuch differences. Therea resomee xampless uggestingthatt he variation ina drug-metabolisinge nzymeb ecomesclinically important only whent he drugi sp resent -thatis,i tisimmaterialw hen absent,the bearero fthe variant beingaperfectly healthy subject. Int hiscase, the variant must represent arandom mutation. Ino thercases,the variant mayaffectt he healthof subjects -whetherorn ot adrugi spresent. For example, the haemolysis-associated deficiencyint he primaquine-metabolisingg lucose-6-phosphated ehydrogenase(G6PD)enzyme 8, 9 protects affected subjects against malarialinfection by Plasmodium. 36 Inconsequence,G 6PD deficiencyo ccurs frequently ins ometropicalcountriesbut isabsent incentral Europe.Genetic alterations represent fitness differencesr ather thanr andomness.
Thesepharmacogenetic datac ontradicts tatements, obviously politically influenced, thatethnically defined human populations areg enetically indistinguishable;t hisn ot true. For example, Cavalli-Sforzaa ndh iscolleaguest ested 120 allelef requenciesin42geographically separated human populations. 37 Theyfoundmany differences,which they summarised bydescribingnineg enetically distinguishable population clusters;Africans differed most fromall others. Since anethnic difference inadrugresponsemaybe clinically important,the possibility ofsuch differencesm ust be considered duringthe development ofanewdrug.
Multifactorialv ariation
Asdescribed, pharmacogeneticss tarted withthe recordingof differencesindrugmetabolism or drugresponsed ueto an alteration inaspecifiedprotein,i ndicatingvariation ina particulargene.Mostdifferencesbetweenindividuals or populations,h owever,a renot caused byasingleg enetic variant but byv ariationsin,a ndc ooperation between,many genes,usually contributed to byenvironmentalfactors. This generalr ulea lso appliest op harmacogenetics.
The differencesbetweenp eoplemaybe caused bya numbero fvariant genesw hich mayinteractandb yv ariable expression ofg enes; environmentalfactorsu sually contribute to the variation. The expression ofagenemaybe affected by othergenes,or byhormones,foodsordrugs; 38 drugeffects on geneexpression havebeenknown for alongtime, asaresult of findingthatthe application ofadrugenhanced its metabolism. Thus,multifactorialv ariation iscomplexandi ts causesare usuallyu nknown.
Fromapracticalp oint ofview,the fundamentalq uestion is oftent odiscovert he magnitude ofthe genetic ande nvironmentalcontributions to ag ivenv ariation,usually expressed int ermso fh eritability.The traditionalw ayt oanswert his question isv ia atwins tudy,thatis,astudycomparingthe within-pairdifferencesinidenticalandfraternalpairs oftwins. Atwins tudyist he only means assessingthe heritability ofadiseaseor ofa ny constant biologicalcharacteristic. Inaddition,pharmacogenetic differenceshaveoftenbeen tested byt wins tudies. 39 Int hiscase, however,a nalternativemethodi savailable. 40 Since ad ruge ffectcomesandg oes,onec anapply ad rug twoo rm oretimest oag ivenp erson andon each occasion q HENRYSTEWART PUBLICATIONS 1473-9542. HUMANG ENOMICS .VOL1. NO 5.375-380AUGUST 2004 measurethe drugresponseor metabolism. Since the person's genesarethe same, any difference inr esponsec ano nly have environmentalcauses. Bygivingadrugtwice to ag roup of people, onec ancomparethe magnitude ofthe within-person andthe between-person variations. Since the between-person variationsw ill be caused byamixtureofg enetic and environmentalfactors,the comparison reveals the magnitude ofh eritability. 40 
Pharmacogeneticsand pharmacogenomics
Ass tated int he Introduction,the transition ofpharmacogeneticsinto pharmacogenomicsreflects technicalimprovements which havec hanged someoutlooks. Thed evelopment of methodst hatallowhigh-throughput screeningofg enesm ade itp ossibleto assess the presence ofvariant structuresin many genesatt he sametime. 41 Thus,onec ouldlooka tt he genomea ndnot just the variation ofoneor othergeneof interest. Lookinga tt he genome 42 revealed the factt hato nly about 3p ercent ofthe DNA structuresinitaretraditional genesw hich function asp roteinp roducers.We still haveto strugglewithquestions regardingthe function ofmost ofour DNAs. Ino therw ords,the traditionals cience ofg enetics widened into genomicsandwenowhavetwoo verlapping sciencesw hich sharemuch basic information.
'Overlapping'm eans thatbothsciencesp ursuethe same aim; pinpointingg enetic alterations which affectdrug responses. Theg enomic methodologiesm ayimprovethe rate ofd etection ofsuch alterations,h owever. Thesemethodologiespermit,inaddition,somepreviously almost impossible investigations,whoseoutcomesp romiseto strongly affect pharmacologyand, thereby,pharmacogenetics.
Most common diseasesared ueto numerous,ofteninteracting, genes,withe nvironmentalfactors contributingto a greatero rl esserextent,a ndg enomic methodologiesareused inthe search for such disease-associated genes. 43 Thedetection ofsuch ageneprobably means thatanewdrugtargethasbeen identified;t he targetm aybe the genei tselfor the protein encoded byt he gene.Such afi ndingwouldstimulatethe search for chemicals thatfitt he targetandwhich thereby becomenewdrugsw hich help to curethe disease.
Thiss ituation iso ftencomplicated byt he factt hata somewhatdifferent seto fg enesm aycausethe samed iseasei n different people.Inotherwords,theremaybe variations inthe disease-contributingg enes. 44 Thiscouldmeant hatdifferent drugsm ayhaveto be used to combatt he samed iseasei n different people.Determination ofwhich drugto usei n which person will againr equireg enomic screening.
Thus,pharmacogenomicsm ayconcern us withakindof variation which wasu nknown andunsuspected att he time whenp harmacogeneticsr uled.
Personalised medicine
Since practicallyall drugeffects are, to someextent,genetically controlled, personalised medicinemeans thatt he choiceof drugf or any individualw ill haveto be determined mainlyby thatp erson'sgenes. Thishasm any implications.
Int he firstp lace,i no rdert om akea ny genetic test results clinically useful,theym ust be interpreted int ermso fpharmacogenetics. Perhaps the futurephysicianw ill be better trained ingeneticsthaniscurrently the case;perhaps therewill be pharmacogenetic specialists whow ill interprett he dataf or the physician; or perhaps appropriatec omputerp rograms can be developed which will provide the necessary information to the physician. But the most effectivewayt ointroduce pharmacogeneticsinto clinicalm edicinemaybe ac hange in regulatoryandi ndustrialp olicies; thatis,to provide information on which (if any) genesareknown to affectt he action ofa ny drugto be prescribed. 45 Secondly,anumberoflegalandethicalquestionshaveto be resolved.Knowledge ofaperson'sgenesm ayallowanassessment ofstateofh ealth, diseaseprobabilitiesandofprobable life span-a ll items ofi nterest to insurance companies. Isa person the ownero fh iso rhergenes,or ofh iso rhergenetic test results? Aretherelegalr ulesfor the medicalu seofsuch results?
Thirdly,i fthe person'sgenetic make-up hast obe established, whow ill beart he costso fthe genetic tests? Onec an only hopethatt he costs will lessenast imeg oeso n.
If thesethree problems aresolved, the road towardsp ersonalised medicinei so pen. Afi rsts tepcouldb ea ssigningthe patient to ag enetically similarp opulation group.Betweenperson differencest endto be smallerw ithinag enetically defined population thaninarandom population. Beforeone knows ag ivenp atient'sgenes,h iso rherassignment to such a population couldsomewhatr educe the chance ofe ncounteringunexpected reactions. Thus,treatingthe patient asa membero faknown population,e veno fageographically or ethnically defined group,couldbeasmall stepinour efforts to createpersonalised medicine.
Evenif oneh asl ocated ag enewhich ischangedi nagiven person,however,twoproblems remain. First,agivengenemay be mutated inmany different ways. 46 Theremaybe anabsence ofaprotein,afunctionaldecreaseor achange inproperties,for example, affectingvarious drugsdifferently.Thism aycause difficulties. For example, cytochromeC YP2D6m etabolises debrisoquinei nbothaEuropeananda nAfricanp opulation, but anAfricanv ariant metabolisesdebrisoquineb ut not metropolol. 47 Secondly,the expression,a ndtherebyfunction, ofagenemaybe changedb ygenei nteractions,h ormoneso r environmentalfactorsl ikef oodsandd rugs. 48 Thus,i dentification ofafunctionalgenestill leavesu ncertainties.
Whateverw ed o,nowo rint he future, creation ofpersonalised medicinei saworthwhilea im,b ecausei tr epresents aneffortt oimproveaperson'schance ofahealthyl ife;
Humanpharmacogenomics:T he development ofascience Review HISTORICAL PERSPECTIVE however,personalised medicinewill neverbe atruly reliable science.For example, environmentsm aychange and, more specifically,g enee xpression maychange;all predictions based on genestructurethereforerepresent functionall ikelihoods but not certainties.
We will always haveto livealife ofprobabilities.
